Your institution may have access to this item. Find your institution then sign in to continue.
Title
Poster: HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL).